The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

• DOI: 10.1200/jco.2025.43.16_suppl.e20501
• Publication Date: 2025-05-28T17:47:41Z
• Authors: Nedim Turan; Timucin Cil; Mehmet Artac; Ilhan Hacibekiroglu; Ahmet Taner Sümbül; Dogan Uncu; Akin Ozturk; Abdurrahman Isikd...; Sema Sezgin Goksu; Ozturk Ates; Nuri Karadurmus; Mehmet Ali Nahit ...; Lokman Koral; Mehmet Bilici; Umut Demirci; Emir Celik; Cagatay Arslan; Haci Mehmet Turk; Bekir Hacioglu; Mahmut Gumus

e20501 Background: The role of biomarkers in the treatment non-small cell lung cancer is increasing. Biomarker evaluation performed almost all diagnosed patients and treatments are applied according to this evaluation. In study, frequency testing rates with Turkey were investigated. Methods: "Registurk-Lung" study conducted our country, histopathological, molecular, radiological clinical data more than 9000 from 42 centers collected between December 2021 January 2024 within scope observational study. Results: median age was 65 (25-97) years 15,1% female. 60,3% had non-squamous histology 39,7% squamous histology. When we examined alteration rates, EGFR mutation 11,1%, ALK rearrangement 3,2%, ROS-1 1.3%, BRAF 3,6%, MET 2,2%, RET fusion 0,6%, KRAS G12C 17,3%, HER-2 1,2%, NTRK gene fusions 0,14 %. PDL-1 expression level negative (<1%) 33,9 % patients. rate levels greater 50% 26,8%, while 1-49% 39,3% While single biomarker targeted tests (IHC, PCR, FISH...) as a main method, comprehensive genomic analysis (CGA, NGS) only 8,9% As result analysis, druggable detected 17% most important obstacle detection determined insufficiency evaluated tissue. Conclusions: An awareness has been raised about use Turkey. This identification directing will benefit terms survival adherence.